ASP Isotopes (NASDAQ:ASPI) COO Robert Ainscow Sells 25,000 Shares

ASP Isotopes Inc. (NASDAQ:ASPI) COO Robert Ainscow sold 25,000 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $3.90, for a total transaction of $97,500.00. Following the transaction, the chief operating officer directly owned 2,256,879 shares of the company’s stock, valued at approximately $8,801,828.10. This represents a 1.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Robert Ainscow also recently made the following trade(s):

• On Monday, June 8th, Robert Ainscow sold 8,438 shares of ASP Isotopes stock. The shares were sold at an average price of $7.00, for a total transaction of $59,066.00.

ASP Isotopes Stock Up 7.7%

Shares of ASPI stock traded up $0.30 during trading hours on Friday, hitting $4.20. 3,831,544 shares of the company were exchanged, compared to its average volume of 2,936,087. The company has a debt-to-equity ratio of 0.76, a quick ratio of 3.85 and a current ratio of 3.87. ASP Isotopes Inc. has a one year low of $3.51 and a one year high of $14.49. The business’s 50-day simple moving average is $4.37 and its two-hundred day simple moving average is $5.20. The stock has a market capitalization of $643.90 million, a price-to-earnings ratio of -3.18 and a beta of 3.59.

ASP Isotopes (NASDAQ:ASPI) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.11). The firm had revenue of $5.12 million during the quarter, compared to analyst estimates of $4.47 million. ASP Isotopes had a negative return on equity of 64.99% and a negative net margin of 427.98%.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Wall Street Zen upgraded ASP Isotopes from a “strong sell” rating to a “sell” rating in a report on Saturday, August 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of ASP Isotopes in a research note on Wednesday, June 24th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, ASP Isotopes presently has an average rating of “Hold” and an average target price of $13.00.

Institutional Investors Weigh In On ASP Isotopes

A number of institutional investors have recently modified their holdings of the business. Quantbot Technologies LP acquired a new stake in ASP Isotopes during the third quarter worth about $34,000. BNP Paribas Financial Markets boosted its stake in ASP Isotopes by 84.9% in the second quarter. BNP Paribas Financial Markets now owns 5,549 shares of the company’s stock valued at $41,000 after acquiring an additional 2,548 shares during the period. State of Wyoming acquired a new position in ASP Isotopes in the first quarter valued at approximately $29,000. Allworth Financial LP bought a new position in shares of ASP Isotopes during the second quarter valued at approximately $51,000. Finally, Legal & General Group Plc grew its holdings in shares of ASP Isotopes by 30.4% during the third quarter. Legal & General Group Plc now owns 8,377 shares of the company’s stock valued at $81,000 after purchasing an additional 1,953 shares during the last quarter. Institutional investors own 16.80% of the company’s stock.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.